Infigratinib Before Surgery for the Treatment of Upper Tract Urothelial Cancer
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
This phase Ib trial studies the side effects of infigratinib before surgery in treating
patients with upper tract urothelial cancer. Infigratinib may stop the growth of tumor cells
by blocking the activities of a gene called FGFR needed for cell growth. Giving infigratinib
before surgery may cause the tumor to shrink, which may make the surgical procedure easier
and/or reduce the need for more extensive surgery.